If all had gone as planned, December 31 should have been a long-awaited celebration day for Outlook Therapeutics. The company would not only have marked the upcoming New Year but also celebrated Lytenava, its core product, securing access to the U.S. market—a critical lifeline for its survival.

According to the 2025 fiscal year results released in December, Outlook generated $1.4 million in revenue, primarily driven by Lytenava’s initial commercial sales in Germany and the UK starting June 2025. While this figure is far from impressive, it still stands as a significant milestone compared to the zero revenue recorded in fiscal year 2024.

However, the harsh reality remains that $1.4 million is a drop in the bucket for sustaining the company’s operations. The gross profit was a meager $60,000, as the cost of revenue nearly offset the total sales. Moreover, the net loss attributable to Outlook during the reporting period remained as high as $62.4 million.

The cash flow situation is equally grim. By the end of fiscal year 2025, Outlook’s cash and cash equivalents stood at a mere $8.1 million. Even when adding the $14.9 million in net proceeds from the at-the-market stock offerings conducted in the second half of 2025, analysts estimate that the company’s monthly operating cash burn ranges from $5.5 million to $5.6 million. This means the total cash reserves of approximately $23 million will only cover four months of expenses.

In other words, barring any unforeseen variables, Outlook can only sustain its operations until early 2026.

Therefore, the FDA’s third review on December 31 was of paramount importance for this biotech firm striving to transition from the R&D phase to early commercialization. Success would have opened up vast opportunities for growth; failure, however, would have left the company in an extremely precarious position.

Fate, unfortunately, had other plans. The FDA issued a Complete Response Letter (CRL), rejecting Lytenava’s Biologics License Application (BLA) for the treatment of wet age-related macular degeneration (wet AMD). Following the news, Outlook’s stock price plummeted repeatedly, crashing by approximately 80% in after-hours trading.

It is important to note that Lytenava was not a high-risk gamble. Chemically known as bevacizumab-vikg, it is a pharmaceutical formulation specifically designed for ophthalmic use. Essentially, Lytenava is an ophthalmic formulation of bevacizumab, a VEGF monoclonal antibody widely used in cancer treatment.

Its mechanism of action is well-established. Lytenava works by inhibiting vascular endothelial growth factor (VEGF), a key factor contributing to vision loss in patients with wet AMD.

As one of the leading causes of vision loss in the elderly, wet AMD affects millions of people worldwide. The disease occurs when abnormal blood vessels grow and leak in the macula, the central part of the retina at the back of the eye. Administered via intravitreal injection, Lytenava acts directly on the eye to inhibit the growth of these abnormal blood vessels.

Outlook has invested substantial resources and time in developing Lytenava, launching a series of NORSE clinical trials that yielded promising results.

Notably, the design and endpoints of the NORSE EIGHT trial were finalized through the so-called Special Protocol Assessment (SPA) conducted with the FDA. Ultimately, Outlook demonstrated that Lytenava was non-inferior to Lucentis (ranibizumab) at 12 weeks of treatment. Despite this, the FDA still rejected the drug’s marketing application.

Why is this the case? Why did the FDA say “no” to Outlook for the third time?

In Outlook’s official introduction, Lytenava is nothing short of a star product—it is the first approved ophthalmic formulation of bevacizumab.

In May 2024, the European Commission approved Lytenava for the treatment of wet AMD. That July, the UK’s Medicines and Healthcare products Regulatory Agency granted marketing authorization for the drug. In May 2025, Outlook officially launched Lytenava simultaneously in the UK and Germany.

Yet this unstoppable momentum failed to carry over to the U.S. market. On the contrary, Lytenava’s path to gaining FDA approval has been fraught with twists and turns.

The misfortune began in August 2023, when Outlook received its first CRL from the FDA. The agency cited CMC (Chemistry, Manufacturing, and Controls) issues and a lack of substantial efficacy evidence—despite Lytenava meeting its primary endpoint in the NORSE TWO trial.

Seeking Alpha analysts argued that the CMC concerns were understandable. After all, Lytenava is administered via injection into the eye; even minor contamination or formulation defects could lead to irreversible vision loss, an outcome the FDA is determined to avoid. “They enforce standards for sterility, manufacturing consistency, and quality control very rigorously, especially because Lytenava will be used repeatedly in large numbers of patients,” the analyst wrote.

Following intensive efforts, Outlook finally received its second CRL from the FDA in August 2025. While this may seem counterintuitive, the remaining issue was at least narrowed down to just efficacy evidence.

The market was stunned by this second setback—Outlook’s share price plummeted by over 50% on the same day.

First, Lytenava had the backing of the pivotal Phase III NORSE TWO trial, which demonstrated statistically significant and clinically meaningful improvements in visual acuity compared to Lucentis, meeting both primary and key secondary endpoints to support its overall efficacy and safety profile.

Second, to satisfy the FDA’s requirement for a second well-controlled study, Outlook conducted the NORSE EIGHT non-inferiority trial. Enrolling approximately 400 wet AMD patients, the trial initially failed to meet its primary endpoint versus Lucentis at the 8-week mark. Sources revealed that when Outlook submitted Lytenava’s marketing application to the FDA for the second time, data from NORSE EIGHT was only partially available, as the study had not yet been completed.

If the problem had indeed stemmed from the incompleteness of NORSE EIGHT data, then Outlook’s third application in December 2025 should have been a sure win.

“The third resubmission included a considerable number of additional data points,” the Seeking Alpha analyst summarized. “It now incorporates the full NORSE EIGHT non-inferiority trial, which demonstrated non-inferiority to Lucentis at the 12-week mark. This 12-week endpoint should provide additional clinical support beyond the original pivotal NORSE TWO trial.”

As for CMC, Outlook also made further optimizations. Overall, the third submission featured a more comprehensive and robust clinical data package.

The market interpreted this move as Outlook appealing to the FDA—we clearly fell short in the first two attempts, so this time, we have addressed your requirements and hope to earn your approval. Unfortunately, the FDA remained unmoved.

In its announcement, Outlook stated that the FDA still requires “confirmatory evidence of efficacy” but has “not yet indicated what type of confirmatory evidence would be acceptable.”

This biotech firm, which had returned triumphant from the European market, now finds its fate hanging in the balance on its home turf.

The wet AMD market is a vast and fiercely competitive arena. In the United States alone, the anti-VEGF therapy segment generates over $7.7 billion in annual revenue, a market currently dominated by several major pharmaceutical companies.

Eylea (aflibercept) – a collaboration between Regeneron and Bayer – and Roche’s Vabysmo are among the leaders in this space: Eylea posted global sales exceeding $1.7 billion in the third quarter of 2025, while Vabysmo racked up over $3.6 billion in sales in the first three quarters of the same year. Novartis’s Lucentis is also a strong competitor.

However, despite lacking official approval for ophthalmic indications, Avastin (bevacizumab) is used off-label in roughly half of wet AMD treatments in the U.S.

This creates a rather delicate dynamic: established, legally approved products like Lucentis, Eylea, and Vabysmo command high prices and hold solid market shares. The demand for lower-cost alternatives has spawned widespread off-label use of Avastin, yet there is a temporary void in legitimate, cost-effective, and safe substitutes tailored for ophthalmic use.

Outlook set its sights on this massive market, where non-ophthalmic Avastin is commonly repurposed in hospitals for eye treatments. The company aimed to provide an alternative that boasts official indications, meets ophthalmology-specific standards, and offers cost competitiveness.

After the third rejection from the FDA, this vision has become uncertain.

Disappointed with the decision, Outlook’s CEO Bob Jahr disagrees with the FDA’s ruling and stated that the company remains “fully committed to taking all necessary steps to secure approval in the United States.” The catch is that Outlook is not the only contender vying for a foothold in this market.

For instance, in the first quarter of 2026, Ocular Therapeutix will report data from SOL-1, a Phase III trial of its wet AMD treatment Axpaxli. A TKI inhibitor with anti-angiogenic properties, Axpaxli requires administration only once every six months.

If successful, Axpaxli is expected to transform the treatment paradigm for wet AMD. Ocular plans to submit a New Drug Application (NDA) to the FDA shortly after the trial results are released.

EyePoint Pharmaceuticals, a rival of Ocular, is also developing a wet AMD drug with a once-every-six-months dosing schedule, with data expected to be announced in mid-2026. If both companies’ trials prove successful, analysts at Mizuho Securities predict that at least one, if not both, could be acquired by major pharmaceutical firms with existing ophthalmology portfolios.

Further extrapolating this scenario, the combined momentum of a revolutionary product from a biotech firm paired with the commercialization channels of a multinational corporation (MNC) might overshadow Outlook’s first-mover advantage with its in-house production and distribution model.

Outlook’s experience in Europe serves as a case in point. From an operational standpoint, the company adopted a strategy of direct commercialization and targeted regional expansion. It built specialized local teams and established regional distribution networks, such as partnering with Germany’s ContraCare to integrate local distribution and pharmacy sales channels.

In terms of pricing, Outlook was aggressive: Lytenava is priced at £470 in the UK and €751.61 in Germany, positioning it as one of the most affordable drugs on the market. It has also secured formal reimbursement eligibility in England, Wales, Scotland, and Northern Ireland.

Yet even with this seemingly favorable setup, Lytenava only generated $1.4 million in revenue. It is worth noting that after deducting the cost of revenue, the gross profit was a mere $60,000.

Entering the U.S. market is imperative for Outlook. However, its strained cash reserves and the FDA’s ambiguous stance have cast doubt over whether the company can mount a fourth attempt at approval.

On January 5, H.C. Wainwright slashed its target price for Outlook from $1 to $0.5 per share. Subsequent stock performance has shown that it will be an uphill battle for Outlook to recover its lost ground.

On January 6, Outlook made an urgent appointment, naming a new Vice President of Strategy and Business Development to lead the company’s business development initiatives, including strategic partnerships, out-licensing opportunities, and growth plans.

Will this ophthalmic biotech stage a comeback, be acquired by a major player, or fade into obscurity? The answer may not be far off.